FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Dermatology Drugs in Phase I/II Clinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): FB-401

            Therapeutic Area: Dermatology

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Alger

            Deal Size: $25.0 million Upfront Cash: Undisclosed

            Deal Type: Merger February 19, 2020

            Details:

            The merged company will focus on advancing Forte's clinical program in inflammatory skin diseases, including atopic dermatitis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): B-VEC

            Therapeutic Area: Dermatology

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Investment January 24, 2020

            Details:

            Krystal Biotech intends to make the clinical material for an upcoming phase 3 trial of B-VEC at its Ancoris facility and anticipates starting the trial in Q1 2020.